Brief: Revive Therapeutics Provides Update Of Psilocybin Pharmaceutical Programs
17/01/2022 13:47
Jan 17 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE OF PSILOCYBIN
PHARMACEUTICAL
PROGRAMS
* REVIVE THERAPEUTICS LTD - IRB APPROVAL TO INITIATE PHASE 2
STUDY
FOR METHAMPHETAMINE ABUSE DISORDERS
* REVIVE THERAPEUTICS LTD - ENTERED INTO A RESEARCH
COLLABORATION
AGREEMENT WITH PHARMATHER HOLDINGS LTD
* REVIVE THERAPEUTICS - EXPECTS TO COMPLETE A RESEARCH-GRADE
BATCH
OF PSILOCYBIN FOR RESEARCH IN Q2-2022 WITH AIM TO CONDUCT
CLINICAL STUDIES IN 2023
Source text for Eikon: ID:nGNX38VCpn
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure